SEC Comment Letter 0000000000-24-007675 to INTENSITY THERAPEUTICS, INC. (INTS)
INTENSITY THERAPEUTICS, INC.
Date: July 8, 2024 · CIK: 0001567264 · Accession: 0000000000-24-007675
AI Filing Summary & Sentiment
File numbers found in text: 333-280684
Letter
July 8, 2024 Lewis H. Bender President, Chief Executive Officer and Chairman Intensity Therapeutics, Inc. 1 Enterprise Drive, Suite 430 Shelton, CT 06484-4779 Re:Intensity Therapeutics, Inc. Registration Statement on Form S-3 Filed July 3, 2024 File No. 333-280684 Dear Lewis H. Bender: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Jeffrey P. Schultz
Show Raw Text
July 8, 2024
Lewis H. Bender
President, Chief Executive Officer and Chairman
Intensity Therapeutics, Inc.
1 Enterprise Drive, Suite 430
Shelton, CT 06484-4779
Re:Intensity Therapeutics, Inc.
Registration Statement on Form S-3
Filed July 3, 2024
File No. 333-280684
Dear Lewis H. Bender:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Jeffrey P. Schultz